Abstract | BACKGROUND AND OBJECTIVES: Bone marrow angiogenesis is increased in patients with multiple myeloma (MM) and correlates with disease stage. DESIGN AND METHODS: RESULTS: In this report we used quantitative flow cytometry to study cytoplasmic VEGF (cyVEGF) expression (measured as antibody binding capacity) in plasma cells from patients with MM (n = 22), MGUS/SMM (n = 12), and AL-amyloidosis (AL) (n = 9). CyVEGF expression was higher in MM (169,591) than in MGUS/SMM (144,858), or AL (106,011) although these differences were not statistically significant. Using an indirect VEGFR assay that measures VEGF binding, we found VEGF receptors on plasma cells from all groups of patients, with the lowest expression on plasma cells from normal individuals. We detected VEGF R1, VEGF R2, and VEGF R3 on plasma cells from all groups of patients and found receptor expression predominantly in the subset of CD45-positive plasma cells. INTERPRETATION AND CONCLUSIONS: This study supports the concept that VEGF is involved in the pathogenesis of MM, and suggests that VEGF may differentially affect a subset of plasma cells.
|
Authors | Teresa Kimlinger, Michael Kline, Shaji Kumar, John Lust, Thomas Witzig, S Vincent Rajkumar |
Journal | Haematologica
(Haematologica)
Vol. 91
Issue 8
Pg. 1033-40
(Aug 2006)
ISSN: 1592-8721 [Electronic] Italy |
PMID | 16870555
(Publication Type: Comparative Study, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Vascular Endothelial Growth Factor A
- Receptors, Vascular Endothelial Growth Factor
|
Topics |
- Bone Marrow Cells
(pathology, physiology)
- Gene Expression Regulation, Neoplastic
- Humans
- Multiple Myeloma
(metabolism, pathology)
- Plasma Cells
(metabolism, pathology)
- Receptors, Vascular Endothelial Growth Factor
(metabolism)
- Reference Values
- Vascular Endothelial Growth Factor A
(metabolism)
|